{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T19:52:42Z","timestamp":1762026762474,"version":"build-2065373602"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2020,10,9]],"date-time":"2020-10-09T00:00:00Z","timestamp":1602201600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,10,9]],"date-time":"2020-10-09T00:00:00Z","timestamp":1602201600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Mol Hist"],"published-print":{"date-parts":[[2020,12]]},"DOI":"10.1007\/s10735-020-09912-6","type":"journal-article","created":{"date-parts":[[2020,10,9]],"date-time":"2020-10-09T15:02:49Z","timestamp":1602255769000},"page":"659-673","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Long non-coding RNAs as targets for immunosuppressive drug teriflunomide in anti-cancer potential for hepatocellular carcinoma"],"prefix":"10.1007","volume":"51","author":[{"given":"Yinkai","family":"Xu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daoming","family":"Shen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jianxia","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaolan","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Junhao","family":"Tu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lei","family":"Qin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Liyang","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Haixin","family":"Qian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fengbao","family":"Guo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,10,9]]},"reference":[{"key":"9912_CR1","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1016\/j.jss.2013.05.089","volume":"185","author":"A Alhefdhi","year":"2013","unstructured":"Alhefdhi A, Burke JF, Redlich A, Kunnimalaiyaan M, Chen H (2013) Leflunomide suppresses growth in human medullary thyroid cancer cells. J Surg Res 185:212\u2013216","journal-title":"J Surg Res"},{"key":"9912_CR2","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1038\/nrc3419","volume":"13","author":"JN Anastas","year":"2013","unstructured":"Anastas JN, Moon RT (2013) WNT signalling pathways as therapeutic targets in cancer. Nat Rev Cancer 13:11\u201326","journal-title":"Nat Rev Cancer"},{"key":"9912_CR3","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1007\/s40265-014-0212-x","volume":"74","author":"A Bar-Or","year":"2014","unstructured":"Bar-Or A, Pachner A, Menguy-Vacheron F, Kaplan J, Wiendl H (2014) Teriflunomide and its mechanism of action in multiple sclerosis. Drugs 74:659\u2013674","journal-title":"Drugs"},{"key":"9912_CR4","first-page":"161","volume":"23","author":"JF Bromberg","year":"2001","unstructured":"Bromberg JF (2001) Activation of STAT proteins and growth control. BioEssays: news and reviews in molecular. Cell Dev Biol 23:161\u2013169","journal-title":"Cell Dev Biol"},{"key":"9912_CR5","doi-asserted-by":"publisher","first-page":"1501","DOI":"10.1016\/j.molonc.2015.06.005","volume":"9","author":"M Bupathi","year":"2015","unstructured":"Bupathi M, Kaseb A, Meric-Bernstam F, Naing A (2015) Hepatocellular carcinoma: Where there is unmet need. Mol Oncol 9:1501\u20131509","journal-title":"Mol Oncol"},{"key":"9912_CR6","doi-asserted-by":"publisher","first-page":"1117","DOI":"10.1053\/j.gastro.2006.01.006","volume":"130","author":"DF Calvisi","year":"2006","unstructured":"Calvisi DF, Ladu S, Gorden A, Farina M, Conner EA, Lee JS, Factor VM, Thorgeirsson SS (2006) Ubiquitous activation of Ras and Jak\/Stat pathways in human HCC. Gastroenterology 130:1117\u20131128","journal-title":"Gastroenterology"},{"key":"9912_CR7","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1016\/j.ejmech.2012.07.023","volume":"55","author":"KF Chen","year":"2012","unstructured":"Chen KF, Tai WT, Hsu CY, Huang JW, Liu CY, Chen PJ, Kim I, Shiau CW (2012) Blockade of STAT3 activation by sorafenib derivatives through enhancing SHP-1 phosphatase activity. Eur J Med Chem 55:220\u2013227","journal-title":"Eur J Med Chem"},{"key":"9912_CR8","doi-asserted-by":"publisher","first-page":"115","DOI":"10.3322\/caac.21338","volume":"66","author":"W Chen","year":"2016","unstructured":"Chen W, Zheng R, Baade PD, Zhang S, Zeng H, Bray F, Jemal A, Yu XQ, He J (2016) Cancer statistics in China, 2015. Cancer J Clin 66:115\u2013132","journal-title":"Cancer J Clin"},{"key":"9912_CR9","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/j.clim.2011.02.011","volume":"142","author":"MC Claussen","year":"2012","unstructured":"Claussen MC, Korn T (2012) Immune mechanisms of new therapeutic strategies in MS: teriflunomide. Clin Immunol 142:49\u201356","journal-title":"Clin Immunol"},{"key":"9912_CR10","doi-asserted-by":"publisher","first-page":"1270","DOI":"10.1021\/bi952168g","volume":"35","author":"JP Davis","year":"1996","unstructured":"Davis JP, Cain GA, Pitts WJ, Magolda RL, Copeland RA (1996) The immunosuppressive metabolite of leflunomide is a potent inhibitor of human dihydroorotate dehydrogenase. Biochemistry 35:1270\u20131273","journal-title":"Biochemistry"},{"key":"9912_CR11","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1007\/s10911-006-9014-4","volume":"11","author":"S Desrivieres","year":"2006","unstructured":"Desrivieres S, Kunz C, Barash I, Vafaizadeh V, Borghouts C, Groner B (2006) The biological functions of the versatile transcription factors STAT3 and STAT5 and new strategies for their targeted inhibition. J Mamm Gland Biol Neoplasia 11:75\u201387","journal-title":"J Mamm Gland Biol Neoplasia"},{"key":"9912_CR12","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1586\/17512433.2015.1019343","volume":"8","author":"YD Fragoso","year":"2015","unstructured":"Fragoso YD, Brooks JB (2015) Leflunomide and teriflunomide: altering the metabolism of pyrimidines for the treatment of autoimmune diseases. Expert Rev Clin Pharmacol 8:315\u2013320","journal-title":"Expert Rev Clin Pharmacol"},{"key":"9912_CR13","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1593\/neo.10168","volume":"12","author":"N Hail","year":"2010","unstructured":"Hail N, Chen P, Bushman LR (2010) Teriflunomide (Leflunomide) promotes cytostatic, antioxidant, and apoptotic effects in transformed prostate epithelial cells: evidence supporting a role for teriflunomide in prostate cancer chemoprevention. Neoplasia 12:464\u2013475","journal-title":"Neoplasia"},{"key":"9912_CR14","doi-asserted-by":"publisher","first-page":"1234","DOI":"10.1007\/s10495-010-0518-4","volume":"15","author":"N Hail Jr","year":"2010","unstructured":"Hail N Jr, Chen P, Rower J, Bushman LR (2010) Teriflunomide encourages cytostatic and apoptotic effects in premalignant and malignant cutaneous keratinocytes. Apoptosis 15:1234\u20131246","journal-title":"Apoptosis"},{"key":"9912_CR15","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1007\/s10495-011-0667-0","volume":"17","author":"N Hail Jr","year":"2012","unstructured":"Hail N Jr, Chen P, Kepa JJ, Bushman LR (2012) Evidence supporting a role for dihydroorotate dehydrogenase, bioenergetics, and p53 in selective teriflunomide-induced apoptosis in transformed versus normal human keratinocytes. Apoptosis 17:258\u2013268","journal-title":"Apoptosis"},{"key":"9912_CR16","doi-asserted-by":"crossref","unstructured":"He D, Zhang C, Zhao X, Zhang Y, Dai Q, Li Y, Chu L (2016) Teriflunomide for multiple sclerosis. Cochrane Database Syst Rev 3:CD009882","DOI":"10.1002\/14651858.CD009882.pub3"},{"key":"9912_CR17","doi-asserted-by":"publisher","first-page":"2502","DOI":"10.1016\/j.ejca.2005.08.016","volume":"41","author":"DR Hodge","year":"2005","unstructured":"Hodge DR, Hurt EM, Farrar WL (2005) The role of IL-6 and STAT3 in inflammation and cancer. Eur J Cancer 41:2502\u20132512","journal-title":"Eur J Cancer"},{"key":"9912_CR18","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1177\/1535370214554881","volume":"240","author":"O Huang","year":"2015","unstructured":"Huang O, Zhang W, Zhi Q, Xue X, Liu H, Shen D, Geng M, Xie Z, Jiang M (2015) Teriflunomide, an immunomodulatory drug, exerts anticancer activity in triple negative breast cancer cells. Exp Biol Med (Maywood) 240:426\u2013437","journal-title":"Exp Biol Med (Maywood)"},{"key":"9912_CR19","doi-asserted-by":"publisher","first-page":"1063","DOI":"10.1016\/j.bbagen.2013.10.035","volume":"1840","author":"P Johnsson","year":"2014","unstructured":"Johnsson P, Lipovich L, Grander D, Morris KV (2014) Evolutionary conservation of long non-coding RNAs; sequence, structure, function. Biochim Biophys Acta 1840:1063\u20131071","journal-title":"Biochim Biophys Acta"},{"key":"9912_CR20","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/S0378-1119(02)00398-0","volume":"285","author":"T Kisseleva","year":"2002","unstructured":"Kisseleva T, Bhattacharya S, Braunstein J, Schindler CW (2002) Signaling through the JAK\/STAT pathway, recent advances and future challenges. Gene 285:1\u201324","journal-title":"Gene"},{"key":"9912_CR21","doi-asserted-by":"publisher","first-page":"7486","DOI":"10.3748\/wjg.v22.i33.7486","volume":"22","author":"LJ Liu","year":"2016","unstructured":"Liu LJ, Xie SX, Chen YT, Xue JL, Zhang CJ, Zhu F (2016) Aberrant regulation of Wnt signaling in hepatocellular carcinoma. World J Gastroenterol 22:7486\u20137499","journal-title":"World J Gastroenterol"},{"key":"9912_CR22","doi-asserted-by":"crossref","unstructured":"Mall JW, Myers JA, Xu X, Saclarides TJ, Philipp AW, Pollmann C (2002) [Leflunomide reduces the angiogenesis score and tumor growth of subcutaneously implanted colon carcinoma cells in the mouse model]. Der Chirurg; Zeitschrift fur alle Gebiete der operativen Medizen 73, 716\u2013720","DOI":"10.1007\/s00104-002-0453-1"},{"key":"9912_CR23","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1159\/000091251","volume":"212","author":"P Nash","year":"2006","unstructured":"Nash P, Thaci D, Behrens F, Falk F, Kaltwasser JP (2006) Leflunomide improves psoriasis in patients with psoriatic arthritis: an in-depth analysis of data from the TOPAS study. Dermatology 212:238\u2013249","journal-title":"Dermatology"},{"key":"9912_CR24","first-page":"1167","volume":"3","author":"LK Shawver","year":"1997","unstructured":"Shawver LK, Schwartz DP, Mann E, Chen H, Tsai J, Chu L, Taylorson L, Longhi M, Meredith S, Germain L, Jacobs JS, Tang C, Ullrich A, Berens ME, Hersh E, McMahon G, Hirth KP, Powell TJ (1997) Inhibition of platelet-derived growth factor-mediated signal transduction and tumor growth by N-[4-(trifluoromethyl)-phenyl]5-methylisoxazole-4-carboxamide. Clin Cancer Res 3:1167\u20131177","journal-title":"Clin Cancer Res"},{"key":"9912_CR25","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.21387","volume":"67","author":"RL Siegel","year":"2017","unstructured":"Siegel RL, Miller KD, Jemal A (2017) Cancer Statistics, 2017. CA Cancer J Clin 67:7\u201330","journal-title":"CA Cancer J Clin"},{"key":"9912_CR26","doi-asserted-by":"publisher","first-page":"970","DOI":"10.1111\/j.1365-2133.2004.05836.x","volume":"150","author":"JA Tlacuilo-Parra","year":"2004","unstructured":"Tlacuilo-Parra JA, Guevara-Gutierrez E, Rodriguez-Castellanos MA, Ornelas-Aguirre JM, Barba-Gomez JF, Salazar-Paramo M (2004) Leflunomide in the treatment of psoriasis: results of a phase II open trial. Br J Dermatol 150:970\u2013976","journal-title":"Br J Dermatol"},{"key":"9912_CR27","doi-asserted-by":"publisher","first-page":"4989","DOI":"10.1038\/onc.2010.236","volume":"29","author":"S Whittaker","year":"2010","unstructured":"Whittaker S, Marais R, Zhu AX (2010) The role of signaling pathways in the development and treatment of hepatocellular carcinoma. Oncogene 29:4989\u20135005","journal-title":"Oncogene"},{"key":"9912_CR28","doi-asserted-by":"publisher","first-page":"1405","DOI":"10.1016\/S0006-2952(99)00228-2","volume":"58","author":"X Xu","year":"1999","unstructured":"Xu X, Shen J, Mall JW, Myers JA, Huang W, Blinder L, Saclarides TJ, Williams JW, Chong AS (1999) In vitro and in vivo antitumor activity of a novel immunomodulatory drug, leflunomide: mechanisms of action. Biochem Pharmacol 58:1405\u20131413","journal-title":"Biochem Pharmacol"},{"key":"9912_CR29","doi-asserted-by":"publisher","first-page":"145","DOI":"10.3389\/fgene.2015.00145","volume":"6","author":"AA Yarmishyn","year":"2015","unstructured":"Yarmishyn AA, Kurochkin IV (2015) Long noncoding RNAs: a potential novel class of cancer biomarkers. Front Genet 6:145","journal-title":"Front Genet"}],"container-title":["Journal of Molecular Histology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10735-020-09912-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10735-020-09912-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10735-020-09912-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,10,10]],"date-time":"2021-10-10T07:04:55Z","timestamp":1633849495000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10735-020-09912-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10,9]]},"references-count":29,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["9912"],"URL":"https:\/\/doi.org\/10.1007\/s10735-020-09912-6","relation":{},"ISSN":["1567-2379","1567-2387"],"issn-type":[{"type":"print","value":"1567-2379"},{"type":"electronic","value":"1567-2387"}],"subject":[],"published":{"date-parts":[[2020,10,9]]},"assertion":[{"value":"22 April 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 September 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 October 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}